Cantor Fitzgerald Forecasts Increased Earnings for Exagen

Exagen Inc. (NASDAQ:XGN) – Stock analysts at Cantor Fitzgerald boosted their FY2024 EPS estimates for Exagen in a research note issued on Monday, March 10th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will post earnings per share of ($0.84) for the year, up from their previous forecast of ($0.86). Cantor Fitzgerald currently has a “Overweight” rating and a $8.00 target price on the stock. The consensus estimate for Exagen’s current full-year earnings is ($0.88) per share. Cantor Fitzgerald also issued estimates for Exagen’s FY2025 earnings at ($0.41) EPS.

XGN has been the subject of a number of other reports. Canaccord Genuity Group raised their target price on shares of Exagen from $5.00 to $7.00 and gave the company a “buy” rating in a report on Friday, January 3rd. William Blair reaffirmed an “outperform” rating on shares of Exagen in a research note on Wednesday, November 13th.

Exagen Trading Up 18.2 %

XGN stock opened at $3.37 on Wednesday. The firm has a fifty day moving average price of $3.79 and a 200 day moving average price of $3.57. Exagen has a fifty-two week low of $1.30 and a fifty-two week high of $6.22. The company has a debt-to-equity ratio of 1.54, a quick ratio of 4.05 and a current ratio of 4.05. The firm has a market cap of $59.44 million, a PE ratio of -3.59 and a beta of 1.40.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Northern Trust Corp boosted its stake in shares of Exagen by 16.7% during the fourth quarter. Northern Trust Corp now owns 18,375 shares of the company’s stock valued at $75,000 after purchasing an additional 2,630 shares during the period. Palumbo Wealth Management LLC boosted its stake in shares of Exagen by 13.5% during the fourth quarter. Palumbo Wealth Management LLC now owns 86,704 shares of the company’s stock valued at $355,000 after purchasing an additional 10,340 shares during the period. Geode Capital Management LLC boosted its stake in shares of Exagen by 11.9% during the fourth quarter. Geode Capital Management LLC now owns 98,057 shares of the company’s stock valued at $402,000 after purchasing an additional 10,442 shares during the period. Corient Private Wealth LLC purchased a new stake in shares of Exagen during the fourth quarter valued at $45,000. Finally, Virtu Financial LLC purchased a new stake in shares of Exagen during the fourth quarter valued at $46,000. 75.25% of the stock is owned by hedge funds and other institutional investors.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).